CN110248946B - Menin-MLL相互作用的氮杂环庚烷抑制剂 - Google Patents

Menin-MLL相互作用的氮杂环庚烷抑制剂 Download PDF

Info

Publication number
CN110248946B
CN110248946B CN201780077761.9A CN201780077761A CN110248946B CN 110248946 B CN110248946 B CN 110248946B CN 201780077761 A CN201780077761 A CN 201780077761A CN 110248946 B CN110248946 B CN 110248946B
Authority
CN
China
Prior art keywords
group
hydrogen
alkyl
compound
method comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780077761.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110248946A (zh
Inventor
P.R.安吉博
V.潘德
B.黑克
D.J.科罗斯基
O.A.G.克罗勒
A.N.帕特里克
I.N.C.皮拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority claimed from PCT/EP2017/082826 external-priority patent/WO2018109088A1/en
Publication of CN110248946A publication Critical patent/CN110248946A/zh
Application granted granted Critical
Publication of CN110248946B publication Critical patent/CN110248946B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201780077761.9A 2016-12-15 2017-12-14 Menin-MLL相互作用的氮杂环庚烷抑制剂 Active CN110248946B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662434549P 2016-12-15 2016-12-15
US62/434549 2016-12-15
EP17150502 2017-01-06
EP17150502.7 2017-01-06
PCT/EP2017/082826 WO2018109088A1 (en) 2016-12-15 2017-12-14 Azepane inhibitors of menin-mll interaction

Publications (2)

Publication Number Publication Date
CN110248946A CN110248946A (zh) 2019-09-17
CN110248946B true CN110248946B (zh) 2023-05-23

Family

ID=60935807

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780077761.9A Active CN110248946B (zh) 2016-12-15 2017-12-14 Menin-MLL相互作用的氮杂环庚烷抑制剂

Country Status (11)

Country Link
US (2) US10745409B2 (https=)
EP (1) EP3555103B1 (https=)
JP (1) JP7142010B2 (https=)
KR (1) KR102513564B1 (https=)
CN (1) CN110248946B (https=)
AU (1) AU2017376599B2 (https=)
BR (1) BR112019012106A2 (https=)
CA (1) CA3044739A1 (https=)
ES (1) ES2901227T3 (https=)
IL (1) IL267277B (https=)
MX (1) MX391405B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
CN116693546B (zh) * 2022-01-28 2025-06-27 成都先导药物开发股份有限公司 Menin抑制剂及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984941A (zh) * 2009-09-04 2013-03-20 密执安大学评议会 用于治疗白血病的组合物和方法
WO2015191701A1 (en) * 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
CN105188705A (zh) * 2013-03-13 2015-12-23 密歇根大学董事会 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法
WO2016081732A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
JP2005527502A (ja) 2002-02-19 2005-09-15 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシン受容体の部分的および全アゴニスト
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
JP4660199B2 (ja) 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
EP1856128A4 (en) 2005-01-19 2009-12-23 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
WO2010041366A1 (ja) 2008-10-06 2010-04-15 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及び記録媒体
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
EP2646455A4 (en) 2010-12-03 2014-04-02 Epizyme Inc Modulators of histone methyltransferase, and methods of use thereof
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
CN103228195B (zh) 2011-08-01 2016-01-20 奥林巴斯株式会社 插入部形状估计装置
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
MX2017010844A (es) 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2017214367A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
WO2018047598A1 (ja) 2016-09-06 2018-03-15 株式会社スリーボンド 熱硬化型導電性接着剤
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
EP3512857B1 (en) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
AU2017326006B2 (en) 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984941A (zh) * 2009-09-04 2013-03-20 密执安大学评议会 用于治疗白血病的组合物和方法
CN105188705A (zh) * 2013-03-13 2015-12-23 密歇根大学董事会 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法
WO2015191701A1 (en) * 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2016081732A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof

Also Published As

Publication number Publication date
MX391405B (es) 2025-03-21
ES2901227T3 (es) 2022-03-21
JP7142010B2 (ja) 2022-09-26
AU2017376599A1 (en) 2019-08-01
EP3555103A1 (en) 2019-10-23
US20200339594A1 (en) 2020-10-29
IL267277B (en) 2022-04-01
CA3044739A1 (en) 2018-06-21
US20190322685A1 (en) 2019-10-24
EP3555103B1 (en) 2021-09-22
BR112019012106A2 (pt) 2019-10-29
KR20190092518A (ko) 2019-08-07
CN110248946A (zh) 2019-09-17
US10745409B2 (en) 2020-08-18
US11530226B2 (en) 2022-12-20
AU2017376599B2 (en) 2021-10-07
JP2020512290A (ja) 2020-04-23
MX2019007067A (es) 2019-10-15
IL267277A (en) 2019-08-29
KR102513564B1 (ko) 2023-03-22

Similar Documents

Publication Publication Date Title
CN109715634B (zh) Menin-mll相互作用的稠合二环抑制剂
TWI878414B (zh) 經取代之直鏈螺環接衍生物
RU2605096C2 (ru) Пиразолохинолиновое производное
CN104837829B (zh) 抑制剂化合物
CN109689663B (zh) Menin-mll相互作用的螺二环抑制剂
TWI592413B (zh) 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
WO2018109088A1 (en) Azepane inhibitors of menin-mll interaction
KR102784966B1 (ko) Nik 억제제로서 신규 치환된 시아노인돌린 유도체
CA3033239A1 (en) Spiro bicyclic inhibitors of menin-mll interaction
JP7219902B2 (ja) ブルトン型チロシンキナーゼ阻害剤
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
TW202116735A (zh) ２ｈ—吲唑衍生物及其在疾病治療中之用途
US11530226B2 (en) Azepane inhibitors of menin-MLL interaction
JP2024518434A (ja) 置換スピロ誘導体
CN120435473A (zh) 取代的1-苯基-3,4-二氢吡啶并[3,4-d]嘧啶-2-酮衍生物
HK40013646A (en) Azepane inhibitors of menin-mll interaction
HK40015432A (en) Azepane inhibitors of menin-mll interaction
HK40015432B (en) Azepane inhibitors of menin-mll interaction
EA046212B1 (ru) Азепановые ингибиторы взаимодействия менин–mll
HK40113255A (zh) 取代的直链螺环衍生物
HK40071760A (en) Substituted straight chain spiro derivatives
HK40008247A (en) Fused bicyclic inhibitors of menin-mll interaction
HK40007797A (zh) Menin-mll相互作用的螺二环抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013646

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant